Edition:
United Kingdom

miRagen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

6.20USD
21 Aug 2018
Change (% chg)

$0.14 (+2.31%)
Prev Close
$6.06
Open
$6.06
Day's High
$6.24
Day's Low
$6.06
Volume
18,005
Avg. Vol
43,439
52-wk High
$10.68
52-wk Low
$5.01

Latest Key Developments (Source: Significant Developments)

Miragen says MRG-106 continued to be generally well-tolerated at all dose levels
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS INC - ANNOUNCED NEW INTERIM RESULTS FROM PHASE 1 CLINICAL TRIAL OF MRG-106 IN PATIENTS WITH MYCOSIS FUNGOIDES (MF) FORM OF CTCL.MIRAGEN THERAPEUTICS INC - MRG-106 CONTINUED TO BE GENERALLY WELL-TOLERATED AT ALL DOSE LEVELS EVALUATED AS OF DECEMBER 4, 2017.MIRAGEN THERAPEUTICS INC - INITIATED DOSING IN THREE ADDITIONAL ONCOLOGY INDICATIONS.MIRAGEN THERAPEUTICS INC - PLAN TO INITIATE A CONTROLLED PHASE 2 TRIAL IN H2 2018 TO FURTHER EVALUATE POTENTIAL OF MRG-106.  Full Article

Miragen Therapeutics reports third quarter financial results
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Miragen Therapeutics Inc :Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update.Q3 revenue $1.6 million versus $900,000.Q3 revenue view $306,000 -- Thomson Reuters I/B/E/S.Miragen Therapeutics Inc - ‍cash and cash equivalents at september 30, 2017 were $42.8 million, compared to $22.1 million at December 31, 2016​.Miragen Therapeutics Inc - qtrly ‍net loss per share, basic and diluted $0.27​.  Full Article

BRIEF-Miragen Therapeutics Reports Q1 Loss Per Share $0.18

* MIRAGEN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE